Pentraxin-3 in coronary artery disease: A meta-analysis

• Published in: Cytokine (Philadelphia, Pa.) Vol. 119; pp. 197 - 201
• Main Authors: Chu, Yi, Teng, Jiwei, Feng, Pin, Liu, Hui, Wang, Fangfang, Li, Xue
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.07.2019
• Subjects: All-cause mortality; Cardiac events; Coronary artery disease; Meta-analysis; Pentraxin-3; Pentraxin-3; All-cause mortality; Coronary artery disease; Cardiac events; Meta-analysis
• ISSN: 1043-4666; 1096-0023
• DOI: 10.1016/j.cyto.2019.03.017

•Prognostic values of blood pentraxin-3 level in CAD patients have yielded conflicting results.•CAD patients with the highest pentraxin-3 level had an 81% higher risk of all-cause mortality.•CAD patients with the highest pentraxin-3 level had a 77% higher risk of cardiac death.•ACS patients with the highest pentraxin-3 level had a 62% higher risk of cardiac events.•Determination of pentraxin-3 level has potential to improve risk stratification of CAD patients. Studies on the prognostic significance of circulating pentraxin-3 level in patients with coronary artery disease (CAD) have yielded conflicting results. The aim of this meta-analysis was to evaluate the prognostic value of circulating pentraxin-3 level in CAD patients. We made a systematic literature search in Pubmed, Embae, CNKI, Wanfang, and VIP database from their inception to January 10, 2019 for prospective cohort studies that investigated the association between pentraxin-3 level and adverse outcomes in patients with CAD. The outcome measures were all-cause mortality, cardiac death, and cardiac events (cardiac death, nonfatal myocardial infarction, heart failure or coronary revascularization). Multivariable-adjusted risk ratio (RR) with 95% confidence intervals (CI) was pooled for the highest versus the lowest pentraxin-3 group to summarize the predictive value. Nine studies were included, enrolling 5,174 CAD patients. Overall, CAD patients with the highest pentraxin-3 level had an increased risk of all-cause mortality (RR 1.81; 95% CI 1.43–2.28), cardiac death (RR 1.77; 95% CI 1.38–2.26), and cardiac events (RR 1.61; 95% CI 1.16–2.25). However, elevated pentraxin-3 level appeared to not significantly increase the risk of cardiac events (RR 1.63; 95% CI 0.71–3.72) in stable CAD subgroup. In CAD patients, elevated circulating pentraxin-3 level is possibly an independent predictor of all-cause mortality, cardiac death, and cardiac events. However, interpretation of these findings should be with caution due to the small number of studies analyzed.